Evidence map›Paper›PMID 30406565›Full record

ArticleClinical rheumatology2019

Autoantibody and metalloproteinase activity in early arthritis.

Monika Ponikowska, Jerzy Świerkot, Beata Nowak, Lucyna Korman, Piotr Wiland

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Anti-RA33 Antibodies Are Present in Patients With Lyme Disease.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2025
    Observational
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Monika PonikowskaDepartment of Rheumatology and Internal Medicine, Wroclaw University Hospital, Wroclaw, Poland.
Jerzy ŚwierkotDepartment of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland.
Beata NowakDepartment of Pharmacology, Wroclaw Medical University, ul. J. Mikulicz-Radeckiego 2, 50-345, Wrocław, Poland. beata.nowak@umed.wroc.pl.ORCID http://orcid.org/0000-0003-0014-6344
Lucyna KormanDepartment of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland.
Piotr WilandDepartment of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland.
Wroclaw Medical University · PL

Funding

Wroclaw Medical University ST-925
6 · The paper itself

Abstract

objectivesThe aim of the study was to evaluate the frequency of anti-mutated citrullinated vimentin antibodies (a-Sa), anti-citrullinated α-enolase peptide 1 antibodies (a-CEP-1), anti-filaggrin antibodies (AFAs), heterogeneous nuclear ribonucleoprotein compies/anti-RA33-antibodies (a-hnRNP/RA33), anti-carbamylated protein antibodies (a-CarP), and metalloproteinase (MMPs) activity in patients with early inflammatory arthritis (EIA).

methodsSeventy-four patients with EIA: 51 diagnosed with RA (rheumatoid arthritis) and 23 with UA (undifferentiated arthritis), and 20 healthy volunteers were enrolled to the study. Inflammatory markers, rheumatoid factor (RF), and antibodies mentioned above were assessed in all patients.

resultsIn the EIA group, we observed significantly higher concentration of a-CEP-1 (65.8 ± 111.6 RU/mL) than in controls (2.0 ± 0.0 RU/mL). In RF(+) RA patients, we observed higher concentration of a-Sa and a-CEP-1 than in other groups. A-Sa were positive in 69% of RF(+) RA, 37% of RF(-) RA, 26% of UA patients and in 10% of controls. A-CEP-1 were positive in 77% of RF(+) RA patients, in 56% of RF(-) RA patients, in 8.7% of UA patients, but they were negative in controls. In patients with RF(+) RA, positive a-CarP were present statistically significantly more often than in RF (-) RA patients. No statistically significant difference in frequency of a-hnRNP/RA33 and AFA between RF(+) RA, RF(-) RA, and UA was observed.

conclusionsOur results suggest that a-CEP-1 may help in differentiation between RF(-) RA and UA. a-CEP-1 and a-Sa may be useful while diagnosing EIA. a-CarP may be used in differentiation of RA RF(-) and UA. However, a follow-up study is needed to evaluate the prognostic value of analyzed antibodies.

Indexed as

AdultAgedAnti-Citrullinated Protein AntibodiesArthritisArthritis, RheumatoidAutoantibodiesBiomarkers, TumorCase-Control StudiesDNA-Binding ProteinsFemaleFilaggrin ProteinsHeterogeneous-Nuclear RibonucleoproteinsHumansIntermediate Filament ProteinsMaleMatrix Metalloproteinase 3Anti-Citrullinated Protein AntibodiesAutoantibodiesBiomarkers, TumorDNA-Binding ProteinsENO1 protein, humanFilaggrin ProteinsFLG protein, humanHeterogeneous-Nuclear RibonucleoproteinsIntermediate Filament ProteinsMatrix Metalloproteinase 3Matrix Metalloproteinase 9Matrix Metalloproteinases, SecretedMMP3 protein, humanMMP9 protein, humanPhosphopyruvate HydrataseRheumatoid FactorTumor Suppressor ProteinsAnti-carbamylated protein antibodies (a-CarP)Anti-citrullinated α-enolase peptide 1 antibodies (a-CEP-1)Anti-filaggrin antibodies (AFA)Anti-mutated citrullinated vimentin antibodies (a-Sa)Early inflammatory arthritisHeterogeneous nuclear ribonucleoprotein compies/anti-RA33-antibodies (a-hnRNP/RA33)Metalloproteinases (MMP)Rheumatoid arthritis

Identifiers

PMID30406565
OpenAlexW2899950560

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.